Skip to content
Screener

Discontinued — last reported Q3 '25

D&A at other companies

Baxter International logo
Baxter InternationalBAX
$237M-4.0%
CONMED logo
CONMEDCNMD
$7.24M-16.8%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$30.5M+4.1%
Intuitive Surgical logo
Intuitive SurgicalISRG
$24M+650%
Novanta logo
NovantaNOVT
$6.42M-6.6%
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
$163.4M+1.7%

Segments

By segment

See full
Orthopaedics$107M
MedSurg and Neurotechnology:$55M+14.6%

Other financials

Income statement

See full
Revenue$6.6B+9.4%
Gross profit$4.5B+17.1%
Operating income$1.7B+49.1%
Net income$1.3B+44.3%
EPS (diluted)$3.30+44.1%

Balance sheet

See full
Cash & equivalents$3.4B+42.8%
Total debt$14.2B-15.2%
Total assets$47.9B+3.5%

Cash flow

See full
Operating cash flow$1.3B+13.5%
CapEx$202.0M+10.4%
Free cash flow$1.1B+14.1%

Valuation

See full
Market cap$129.28B-9.8%
Enterprise value$140.08B-11.2%
P/E34.7×-14.5×
P/S-1.0×

Profitability

See full
Gross margin65%+0.8pp
Operating margin21.4%+6.2pp
Net margin14.4%+2.2pp
FCF margin18.2%+1.3pp

Returns & leverage

See full
Return on equity32.8%
Debt / equity0.8×
Current ratio2.2×+0.4×

Where this comes from

Reported directly by Stryker in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The source filing: Stryker’s 10-Q, filed October 31, 2025.

Filed
Oct 31, 2025
Fiscal quarter
Q3 FY2025
Calendar quarter
Q3 2025
Accession
0000310764-25-000129
Line itemThree Months / 2025Three Months / 2024Nine Months / 2025Nine Months / 2024
Gross profit$3,852$3,517$11,437$10,266
Research, development and engineering expenses4103771,2221,108
Selling, general and administrative expenses2,0451,8946,4245,562
Amortization of intangible assets189159543467
Goodwill and other impairments73216321
Total operating expenses$2,717$2,432$8,352$7,158
Operating income$1,135$1,085$3,085$3,108
Other income (expense), net(106)(42)(276)(144)

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Stryker's D&A?
Stryker (SYK) reported D&A of $189M in Q3 2025.
How has Stryker's D&A changed year-over-year?
Stryker's D&A increased by 18.9% year-over-year, from $159M to $189M.
What is the long-term trend for Stryker's D&A?
Over 3 years (2021 to 2024), Stryker's D&A has grown at a 0.2% compound annual growth rate (CAGR), from $619M to $623M.
What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

Ask your AI about Stryker's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude